Way; Jeffrey
Patent Applications and Registrations
Patent applications and USPTO patent grants for Way; Jeffrey.The latest application filed is for "engineered organisms and uses thereof in the production of biologics, reagents, diagnostics and research tools".
- Way; Jeffrey - San Francisco CA
- Way; Jeffrey - Cambridge MA
| Patent | Date |
|---|---|
| Engineered Organisms And Uses Thereof In The Production Of Biologics, Reagents, Diagnostics And Research Tools App 20220282263 - Gallagher; Ryan ; et al. | 2022-09-08 |
| Engineered Organisms And Uses Thereof As Living Medicines, Research Tools, Food Products, Or Environmental Tools App 20220228104 - Gallagher; Ryan ; et al. | 2022-07-21 |
| Reducing The Immunogenicity Of Fusion Proteins App 20150141626 - Gillies; Stephen D. ; et al. | 2015-05-21 |
| Reducing the immunogenicity of fusion proteins Grant 8,926,973 - Gillies , et al. January 6, 2 | 2015-01-06 |
| Antibodies to interleukin-6 Grant 8,536,308 - Way , et al. September 17, 2 | 2013-09-17 |
| Reducing The Immunogenicity Of Fusion Proteins App 20120309936 - Gillies; Stephen D. ; et al. | 2012-12-06 |
| Proteins comprising an IgG2 domain Grant 8,066,994 - Gillies , et al. November 29, 2 | 2011-11-29 |
| Reducing the immunogenicity of fusion proteins Grant 7,973,150 - Gillies , et al. July 5, 2 | 2011-07-05 |
| Interleukin-6 Antagonists App 20110038877 - Way; Jeffrey ; et al. | 2011-02-17 |
| Methods of treating cancer comprising administering an interleukin-6 antibody variable region Grant 7,820,155 - Way October 26, 2 | 2010-10-26 |
| Reducing The Immunogenicity Of Fusion Proteins App 20100016562 - Gillies; Stephen D. ; et al. | 2010-01-21 |
| Reducing the immunogenicity of fusion proteins Grant 7,601,814 - Gillies , et al. October 13, 2 | 2009-10-13 |
| IL-7 variants with reduced immunogenicity Grant 7,589,179 - Gillies , et al. September 15, 2 | 2009-09-15 |
| Interleukin-6 antagonists App 20070178098 - Way; Jeffrey ; et al. | 2007-08-02 |
| Erythropoietin forms with improved properties Grant 7,211,253 - Way May 1, 2 | 2007-05-01 |
| Expression technology for proteins containing a hybrid isotype antibody moiety App 20060263856 - Gillies; Stephen D. ; et al. | 2006-11-23 |
| IL-7 variants with reduced immunogenicity App 20060141581 - Gillies; Stephen D. ; et al. | 2006-06-29 |
| Reducing the immunogenicity of fusion proteins App 20060025573 - Gillies; Stephen D. ; et al. | 2006-02-02 |
| Fc-erythropoietin fusion protein with improved pharmacokinetics App 20050202538 - Gillies, Stephen D. ; et al. | 2005-09-15 |
| Enhancing the circulating half-life of interleukin-2 proteins App 20050069521 - Gillies, Stephen D. ; et al. | 2005-03-31 |
| Reducing the immunogenicity of fusion proteins App 20030166877 - Gillies, Stephen D. ; et al. | 2003-09-04 |
| Expression technology for proteins containing a hybrid isotype antibody moiety App 20030044423 - Gillies, Stephen D. ; et al. | 2003-03-06 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 